在患有左心室功能障碍的患者中,血microRNA-143和microRNA-145水平升高
Hirotaka Murase1, Shingo Minatoguchi2, Kazuki Heishima3
1Department of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Heart and vessels
|May 8, 2024
概括
在心脏病患者中,左心室功能障碍的microRNA-143和microRNA-145的血水平升高. 这些微RNA与减少的射出分数相关,可能在抵消心脏功能障碍方面发挥作用.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 生物标志物发现发现
背景情况:
- 微RNA-143和微RNA-145主要表达在血管光滑肌细胞中.
- 血miR-143和miR-145在心脏病患者左心室 (LV) 功能中的作用尚不清楚.
研究的目的:
- 研究各种心脏病患者的血miR-143和miR-145水平与LV功能之间的关联.
- 探索这些microRNA与心声学参数和B型性尿素 (BNP) 水平的相关性.
主要方法:
- 量化逆转录聚合酶链反应 (RT-PCR) 用于测量血miR-143和miR-145水平.
- 心声学评估了LV喷射率 (LVEF) 和LV尺寸.
- 血BNP水平也被量化.
主要成果:
- 与对照组相比,心脏病患者的血miR-143和miR-145水平显著更高.
- 在LVEF<50%的患者中观察到升高的miR-143和miR-145水平,并与LVEF呈反相关性.
- 这些微RNA与LV末缩维度和血BNP水平正相关,反过来与LVEF相反相关.
结论:
- 在患有左心室功能障碍的患者中,血miR-143和miR-145升高.
- 这些microRNA可以作为LV功能障碍的潜在生物标志物,并可能在缓解其进展方面发挥作用.
相关概念视频
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...


